orencia
bristol-myers squibb (nz) limited - abatacept 262.5mg; ; - powder for injection - 250 mg - active: abatacept 262.5mg excipient: hydrochloric acid maltose monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.) orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).
orencia
bristol-myers squibb (nz) limited - abatacept 125.875mg equivalent to abatacept 125mg/ml; ; - solution for injection - 125 mg - active: abatacept 125.875mg equivalent to abatacept 125mg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate nitrogen poloxamer 188 sucrose water for injection - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progress of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthiritis in adults not previously treated with methotrexate. orencia should not be administered concurrently with other dmards (eg. tnf inhibitors, rituximab or anakinra).
videx ec
bristol-myers squibb (nz) limited - didanosine 125mg; - capsule - 125 mg - active: didanosine 125mg excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint tan sw-8010 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.
videx ec
bristol-myers squibb (nz) limited - didanosine 200mg; - capsule - 200 mg - active: didanosine 200mg excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint green sb-4020 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.
videx ec
bristol-myers squibb (nz) limited - didanosine 250mg; - capsule - 250 mg - active: didanosine 250mg excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint blue sb-6018 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.
videx ec
bristol-myers squibb (nz) limited - didanosine 400mg; - capsule - 400 mg - active: didanosine 400mg excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer opacode red s-1-15094 opacode red s-1-15095 purified talc sodium starch glycolate titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.
orencia 250mg/vial
bristol-myers squibb (singapore) pte. ltd. - abatacept - injection, powder, lyophilized, for solution - 262.5mg
baraclude oral solution 0.05mg/ml
bristol-myers squibb (singapore) pte. ltd. - entecavir - solution - 0.05mg/ml
orencia injection 125mg/ml in prefilled syringe
bristol-myers squibb (singapore) pte. ltd. - abatacept - injection - 125mg
coumadin- warfarin sodium tablet
bristol-myers squibb pharma company - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. coumadin is contraindicated in: • pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and use in specific populations (8.1)] . coumadin can cause fetal harm when administered to a pregnant woman. coumadin exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. if coumadin is used during pregnancy or if the patient becomes pregn